Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00099671 · ClinicalTrials.gov registry record · Phase 1
Safety of Interleukin-7 in HIV Infected People Currently Taking Anti-HIV Drugs
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00099671 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 25 participants.
The verdict
NCT00099671, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of a single, under-the-skin dose of interleukin-7 (IL-7) in HIV infected people currently taking anti-HIV drugs.
Interventions
- DRUG Recombinant human interleukin-7
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2005-04 |
| Est. Completion | 2007-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00099671
The ClinicalTrials.gov registry entry for NCT00099671 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Recombinant human interleukin-7 is the first listed.
NCT00099671 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00099671 about?
NCT00099671 is a clinical study titled "Safety of Interleukin-7 in HIV Infected People Currently Taking Anti-HIV Drugs". The purpose of this study is to determine the safety of a single, under-the-skin dose of interleukin-7 (IL-7) in HIV infected people currently taking anti-HIV drugs.
What is the current status of trial NCT00099671?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2005-04. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00099671?
The interventions under investigation include: Recombinant human interleukin-7 (DRUG).
Who is sponsoring clinical trial NCT00099671?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.